Member Info for Doc83

Any reason for J&J or is it the Janssen link?

J&J certainly missed the Covid boat. Considering they are just about the biggest pharma out there, it must have bothered them a bit.

“every trial the company have run from SG16 to sprinter has at least trended towards efficacy (or of course shown exceptional efficacy) and safety data is good, with a + showing on adverse events.”

Which begs Docdaneeka’s question, why hasn’t BP snapped it up long ago and now? Or maybe they have come sniffing but Synairgen have been given the wink elsewhere…

Something must be going on behind the scenes. I can’t believe they have spent the best part of a year since sprinter and not got something positive lined up for the company.

EricDraven - I think you're right. PhillipTan is back...

You mean he wouldn't be professional enough to understand they don't represent Synairgen, and wouldn't help get a potentially life saving drug approved?

How come my post got deleted?! There was nothing in there bad? Just pointing out to iamrich that we're not moaning after one day...we've given it the 3 months timescale quoted!

3/3

QUESTION: What has happened to the commercial hires you took on prior to P3 results?
ANSWER: They are still employed. We need them for when we do get to commercialisation. They are all very experienced, versatile and well connected so are currently helping out with activities to get on a Platform Trial – i.e. their wages are not being wasted.
QUESTION: Why are your RNS’s so restrained when you have good news? (The actual question was much longer, examples given to them etc).
ANSWER: The people we are dealing with (fellow scientists, other pharma cos, regulatory bodies etc) just want the facts presented to them, without frivolous hyperbole. It would likely damage credibility to do it differently.
QUESTION: You have talked about partnering to take SNG forward. With regards to negotiating with any potential partners, is our negotiation position perilously weak? Any partner could simply tell us to go it alone, knowing that we could not afford this.

ANSWER: We had misunderstood this. When Synairgen talk about partnering up, they meant with Platform Trial teams, not another pharma co. Synairgen, for now, intend to independently pursue platform trials to continue to build the case for SNG001.
QUESTION: What are the chances of us commercialising SNG001 within 12 months?
ANSWER: SS: extremely slim. Not impossible, but very unlikely. Cash position was talked about at length, perhaps other attendees can elaborate here, but they did not seem concerned.

2/3

QUESTION: What are the chances of getting onto a large Platform Trial and what are the timescales?
ANSWER: The chances are very high. Pursuing this as fast as possible and engaging with numerous teams around the world. Pretty much the whole Synairgen team is engaged in this activity as a matter of urgency. Can’t really give timescales at this point.

QUESTION: Moving away from the science, Polygon own a significant amount of the company and are now potentially very powerful and influential. They may be here today? (some deliberately funny faces pulled from some of the BOD, we took that as saying “yes, they are here!”). Do you have a dialogue with them, are you in contact? If so, what do you talk about? If not, why not, given they are such a large shareholder? And expanding on all of that, are you happy there is such a large external shareholder (i.e. no seat on the board) who could influence the future direction of the company?
ANSWER: They behave like “normal” institutional investors. Synairgen are happy to have them, they were very supportive pre-February and have continued to be supportive since. They have not sought a seat on the board, and they meet them half yearly as they do with other II’s.
QUESTION: Is an EUA a pathway the company would consider or not?
ANSWER: SS said this is extremely unlikely, with the focus on building as robust a case as possible for SNG001. It was, however, stated that if there was another variant which caused huge numbers of deaths then yes, an EUA could theoretically become more likely. But he reiterated an EUA was unlikely.
QUESTION: Are you continuing with the Managed Access Program?
ANSWER: RM/PM: Less focused on this at the moment as we have lots of other things to focus on. We also found that, sadly, people were coming to this program too late. Noted that on these programs, companies are not allowed to advertise or promote their drugs in any way.
QUESTION: Being positive, let’s say we get on a platform trial, pass it and get SNG commercialised, where do you see its potential? How ambitious are the company?
ANSWER: The general gist was we want it to save lives and want it to be used wherever possible.
QUESTION: Do you ever see it becoming the new Standard of Care? How would the price of SNG001 compare to current SOC?
ANSWER: No reason why not. RM commented that it would represent very good value for money.

1/3
Here is an abridged set of notes from the Q&A at the last AGM. For example, I've removed the questions on when we'll have sprinter peer review and ACTIV data, as we now have those.

This lasted well over an hour and a half. No questions were ducked and from what we could see all were answered as fully and frankly as regulations would allow. We have largely paraphrased as we’re not a computer or memory-men, so take the overall interpretation, rather than holding us to every word. If you want something clarifying, we’ll do our best.

In no particular order:
QUESTION: During the “at haste” discussions with various platform trial providers, regulatory bodies and governments all around the world, does the appetite for therapeutic development still appear to remain or are you noticing it tailing off due to the Covid “fire” regressing and governments being busy with Ukraine etc?
ANSWER: RM: No, not at all. Hospital numbers are still rising – look at the current new variants. No one in the scientific/regulatory/government communities is relaxed about Covid. Bear in mind that other drugs are very “selective” in how well they treat different variants.
SSH: This winter the world’s overall immunity will be low due to vaccines etc, so even things like flu, RSV, common cold will be more severe. Future variants of Covid could also be more severe than those we’ve yet seen.
QUESTION: What about COPD/Asthma?
ANSWER: RM used the phrase “we’re firing a lot of arrows and hopefully at least one will hit the target”. In other words, yes, these are still big potential markets for Synairgen, and they are pursuing every angle and leaving no stone unturned. It was re-iterated that the broad-spectrum and variant agnostic nature of SNG001 makes it an extremely powerful potential product.
QUESTION: Why didn’t you ensure that the SPRINTER trial had more chance of success by picking better/more suitable endpoints etc?
ANSWER: When talking about trial design RM, SSH and PM all chipped in with various points. It was said that when Covid first appeared and the world was in turmoil, no one really knew what the specific endpoints should be. Someone in the audience said that surely it should have been “death prevention”, to which the response was that the governments direction at the time was “get people out of hospital” as the NHS was under huge strain, so this had a bearing on the endpoints. Also, it was stated that endpoints such as mortality (would have) need(ed) a lot more people on the trials – into the thousands. The improvement in SOC was also mentioned as per the February RNS.
QUESTION: How many doses of SNG001 does the company currently have?
ANSWER: “10’s of thousands” of active treatment and placebo.

My gut feeling is that they have been given a nudge on a trial, maybe strive, but obviously don’t know any firm start dates. That’s why they can’t tell us anything and why MrCosts is pi55ed off on a daily basis.

Sparkyboy - “Are we saying it's possible that PI can lose all and this drug still comes to market by others”

Oh hell yeah. I am fairly sure SNG001 will get one last chance to prove itself. Simply because it was close to passing sprinter P3, and if you consider the upside potential relative to the actual cost of a P3 trial is probably 100x, someone will take a chance on it. But whether us long suffering PI’s are around to see anything from it is still very much in the balance.

*beat some light reading!

…”what's the agenda mate you got bummed by MB or something ?”

Lol, can’t be some light reading on LSE on a Sunday afternoon!

Hear hear.

And let’s not forget the recent job hire (I know MrCosts was critical of her having a qualification in beautician work or whatever it was) and the job advert for a medical affairs director. At the AGM, we specifically mentioned the job hires pre sprinter and asked what the hell they could possibly be doing now. I can’t believe they would go hiring further people, especially on $240k per year, without some firm idea of what they’ll be doing and how they’ll be paid for.

Is it a he, is it a she?

Nope, it’s just a *******!

Lol, enjoy your weekend writing on anonymous BBs :-D

Gunto - I love the enthusiasm. I have everything crossed you’re right.

Bigbench - the Chinese are also aware of this and I mentioned some weeks back that they could be getting involved in the background to block this.

Invested for 13 years and first post? PhilipTan, Hamm?

iamrich- I think you need to get real. Sure, there can be delays. But this seems a perennial problem with MATD and MG. If this was a one off, fine. But it’s not and so there has to be some level of concern.

Master - not sure I understand your last line. My average in price is 3.5p so getting close to being back in the red.
I’m not panicking though. It was a punt when I bought in originally and also when topping up, but something has never felt quite right about all this LP business. Philip Malone has even been involved for some time now and still no LP…

I hope I am wrong and we all make some good money soon, because I do agree that the LP will see the shares rerate very decently from here.

Why all the stress all of a sudden? When I was critical last week, I got shot down and told we have until November!

Something just doesn’t smell right here. Why the delays? If central government can overrule local, then why does it take so long to turn on the HP Laserjet and print off a LP for PM?!

Andybe4 - “Why did SPAC’s even get mentioned?”

I don’t know. Why don’t you ask your alter ego, spacman?!